Open AccessClinical Outcomes of Three or More Courses of First-line Chemotherapy for Metastatic Urothelial Carcinoma
Author(s) -
Shohei Kawaguchi,
Kouji Izumi,
Renato Naito,
Suguru Kadomoto,
Hiroaki Iwamoto,
Hiroshi Yaegashi,
Masashi Iijima,
Takahiro Nohara,
Kazuyoshi Shigehara,
Yoshifumi Kadono,
Atsushi Mizokami
Publication year - 2021
Publication title -
cancer diagnosis and prognosis
Language(s) - English
Resource type - Journals
ISSN - 2732-7787
DOI - 10.21873/cdp.10061
Subject(s) - metastatic urothelial carcinoma , medicine , chemotherapy , oncology , immunotherapy , disease , urothelial carcinoma , cancer , bladder cancer
The current standard of care for first-line treatment of locally advanced or metastatic urothelial carcinoma (UC) is platinum-based combination chemotherapy. Recently, immune checkpoint inhibitors have been reported to be effective for UC. Knowing whether immunotherapy or chemotherapy is suitable as first-line treatment is beneficial for patients. A retrospective study was conducted on the clinical outcomes of Japanese patients who received three or more courses of first-line chemotherapy for metastatic UC to assess the outcome of conventional treatments in real clinical situation.